Non-muscle Invasive Bladder Cancer Market Size

By Author: yash
Total Articles: 196
Comment this article

Non-muscle invasive bladder cancer (NMIBC) is cancer found in the tissue that lines the inner surface of the bladder. The bladder muscle is not involved. NMIBC, formerly known as superficial bladder cancer, is a common, heterogeneous disease associated with high rates of recurrence and that often requires lifelong surveillance.

The bladder is a vessel that stores urine produced by the kidneys before excretion. The bladder itself is made up of several tissue layers. The first two layers include the urothelial and the lamina propria layers. The urothelial or mucosal layer makes contact with the bladder contents, while the lamina propria, or submucosal layer, and connects the urothelial layer to the underlying smooth muscle. Bladder cancer is a common malignancy arising from the urothelial cells and is responsible for considerable morbidity and mortality.

The most common symptom of bladder cancer is hematuria, which occurs in 80–90% of patients. Approximately 70% of newly diagnosed cases of bladder cancer are NMIBC, meaning that they are confined to the urothelial and lamina propria layers of the bladder. Among ...
... NMIBCs, around 70% present as Ta lesions (papillary tumor confined to the urothelium), 20% as T1 lesions (tumor invades the lamina propria), and 10% as carcinoma in situ (CIS) (flat, high-grade tumor confined to the urothelial layer).

NMIBC is usually diagnosed with cystoscopic evaluation. Upon diagnosis, the location, number, and morphology of the tumors are recorded. Urinary cytology and upper tract imaging is performed to assess for extravesical urothelial tumors and staging purposes. The common diagnosis method used include cystoscopy, urine cytology, imaging, rigid cystoscopy (Transurethral resection of bladder tumor (TURBT) and blue light cytoscopy).

The high rates of progression and recurrence with current therapies for NMIBC necessitate lifelong active surveillance, making bladder cancer the most expensive cancer to treat from diagnosis to death, as well as driving the need for the development of new therapies in patients with NMIBC. Transurethral resection of bladder tumor (TURBT) with or without intravesical therapy, such as mitomycin C (MMC) or Bacillus Calmette-Guerin (BCG, is the current standard of treatment for NMIBC.

Intravesical BCG is commonly used as an adjuvant treatment after TURBT for intermediate-high-risk NMIBC. Local and systemic side effects are common with BCG and can lead to discontinuation of therapy in up to 20% of patients. However, up to 50% of patients fail BCG, significantly increasing the risk of progression and death. Patients who have failed BCG therapy require radical cystectomy with urinary diversion or chemotherapy and radiation, both of which are associated with considerable morbidity.

The main treatments for when the cancer cells are found only in the bladder’s inner lining (non-muscle-invasive bladder cancer) are surgery, intravesical immunotherapy (BCG) and intravesical chemotherapy. Surgery, on its own or combined with other treatments, is used in most cases. Most people with non-muscle-invasive bladder cancer have an operation called transurethral resection of bladder tumor (TURBT). Cystoscopic tumor resection is preferred in the patients wherein there is a removal of any cancer cells that can be seen at transurethral resection of bladder tumor (TURBT).

Moreover, Keytruda (pembrolizumab) is the only approved drug for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.

DelveInsight’s NMIBC market report gives a thorough understanding of NMIBC by including details such as disease definition, causes, mechanism, biomarkers, and diagnosis.

Read More- NMIBC Market Drugs

https://www.delveinsight.com/report-store/non-muscle-invasive-bladder-cancer-market